Wall Street RegretsThe regret calculator.

What if you'd held ABUS?

A $1,000 investment in Arbutus Biopharma Corporation (ABUS) at the month-end close of 2007-07 would be worth $928 at the close of 2026-09 — -7.2% total return, dividends reinvested. The same $1,000 in the S&P 500, dividends reinvested, would be worth $7,635.

$1,000 since 2007$928Total return-7.2%Multiple0.93×CAGR-0.4%

Your scenario

Dates resolve to the nearest month-end close.
Leave empty for "held until today".
Invested at each month-end. Starts on the buy date.

Result

Worth$928Gain+$-72.07 (-7.2%)Multiple0.9×CAGR-0.4%

    If you'd bought $1,000 at the start of each year

    Value of $1,000 invested on January 1 of each year, held to 2026-09, dividends included.

    2007$9282008$1,1322009$3,5522010$1,1202011$1,0962012$3,4332013$1,0382014$6462015$3402016$1,1572017$2,1022018$1,0202019$1,3452020$1,8532021$1,4512022$1,3242023$2,2102024$2,0602025$1,5752026$1,071

    Every year, $1,000 from 2007

    YearValue of $1,000Year return
    2007$1,000
    2008$319-68.1%
    2009$1,011+217.2%
    2010$1,033+2.2%
    2011$330-68.1%
    2012$1,090+230.7%
    2013$1,752+60.7%
    2014$3,330+90.1%
    2015$978-70.6%
    2016$538-44.9%
    2017$1,110+106.1%
    2018$842-24.2%
    2019$611-27.4%
    2020$780+27.7%
    2021$855+9.6%
    2022$512-40.1%
    2023$549+7.3%
    2024$719+30.8%
    2025$1,057+47.1%
    2026$1,132+7.1%

    Best and worst month-end to buy

    The best single month-end close to have bought ABUS was 2020-03 ($1.01): $1,000 then is $5,099 today. The worst was 2015-01 ($25.61): $1,000 then is $201.

    FAQ

    What would $1,000 in ABUS be worth today?

    A $1,000 investment in Arbutus Biopharma Corporation (ABUS) at the start of 2007 would be worth about $928 today, a total return of -7.2%. Dividends are reinvested in these figures.

    What were the best and worst years for ABUS?

    Arbutus Biopharma Corporation (ABUS)'s strongest calendar year since 2007 was 2012, a +230.7% return — $1,000 held through that year became about $3,307 by year-end. Its weakest year was 2015, at -70.6%.

    Does the calculator include dividends and splits?

    Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.

    How much would $100 per month in ABUS have grown?

    Investing $100 at the end of every month since 2007-07 would have grown to about $34,041 on $23,100 invested.

    Did ABUS beat the S&P 500?

    Over the same period, $1,000 in the S&P 500 with dividends reinvested (the S&P 500 Total Return index) would be worth $7,635. ABUS trailed the S&P 500 by +87.8% in total return.

    Is this investment advice?

    No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.

    Methodology

    Arbutus Biopharma Corporation (ABUS) historical total-return data from 2007-07 to 2026-09, reduced to month-end closes for the tables above.

    Returns use adjusted close prices — adjusted for stock splits and reinvested dividends, the same convention used by major brokerages. End-of-day and live prices come from EODHD; parts of the deep historical series are carried over from Yahoo Finance data. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (EODHD): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.

    Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.

    Full methodology →

    What if you'd held…

    Data: adjusted close prices via EODHD and Yahoo Finance. As of 2026-09-04. Not financial advice.